TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Kivo Health raised $10 million in Series A funding, bringing its total financing to $16 million. The Seattle startup plans to use the money for nationwide expansion of its virtual home-care program, which currently focuses on chronic obstructive pulmonary disease (COPD).
Kivo Health, a Seattle-based virtual home-care startup focused on chronic lung disease, raised $10 million in Series A financing to expand its services nationwide. The round brings the company’s total financing to $16 million and is intended to help it reach more people managing COPD at home.
Allumia Ventures led the funding round, with participation from Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures, according to Home Health Care News. Kivo said the investment will fund national growth and expansion of its care model beyond COPD to other high-cost chronic illnesses.
Kivo’s current program combines at-home equipment and virtual respiratory-therapist support. After enrolling, a patient receives a kit that includes a tablet, oxygen monitor and exercise bands. The patient meets a respiratory therapist online for an assessment and an individual treatment plan. Kivo’s website describes small-group virtual sessions twice a week for nine weeks, covering breathing techniques, targeted exercises and information on managing COPD.
Co-founder and CEO Victor Sadauskas told Home Health Care News that the company has delivered tens of thousands of sessions and provided care to thousands of patients. He said Kivo intends to expand nationwide and serve tens of thousands of patients within two years. The report says the program is covered by Medicare, Medicaid and several commercial health plans, including UnitedHealthcare, Humana, Blue Cross, Aetna and Priority Health.
Scaling Virtual COPD Support
The financing gives Kivo capital to extend a care model that aims to support people with COPD between conventional clinical visits. The company says earlier intervention and ongoing guidance can improve patients’ quality of life and help avoid hospital stays. If the program reaches more patients, its growth could offer health plans and care providers another way to deliver respiratory support outside hospitals and clinics.
Kivo also says its program reduces healthcare spending by $8,245 per member per year, attributing the claimed savings to fewer hospitalizations, emergency-room visits and nursing-home days. That figure is a company-reported claim; the source report does not provide the underlying study design, comparison group or period used to calculate it. The funding announcement alone does not establish that the reported savings will apply across all patients or markets.
The planned move into other costly chronic conditions would broaden the company’s reach, but also represents a step beyond its current COPD focus. Its ability to expand will depend on reaching patients, maintaining clinical support and securing coverage across the areas it targets.
Products Worth Considering
Blueair Blue Pure 211i Max Smart Air Purifier for Large Rooms
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
Blueair Blue Pure 511i Max Air Purifier for Home and Bedroom
As an affiliate, we earn on qualifying purchases.
How Kivo Delivers COPD Care
Kivo’s approach pairs remote clinical contact with equipment used at home, rather than relying solely on occasional appointments. In the program described on its website, patients work with respiratory therapists through a structured nine-week course. The format is designed to teach practical skills and support management of symptoms between visits with a clinician.
The startup’s stated focus is older adults and people living with chronic lung disease. Its expansion plans build on the existing program and its reported payer coverage. The funding announcement does not say which states or patient groups will be targeted first, or whether the nine-week structure will change as the company grows.
“We have delivered tens of thousands of sessions, providing thousands of patients access to care that improves symptoms and saves health plans money by reducing unnecessary hospitalizations, ER visits and nursing home days.”
— Victor Sadauskas, Kivo Health co-founder and CEO, in an email to Home Health Care News
Expansion Details Still Pending
The announcement does not specify how the $10 million will be allocated, which markets Kivo will enter first or when the nationwide expansion will begin. The company’s two-year patient target is a stated plan; the report does not detail the staffing, enrollment or operational milestones behind it.
The source material also does not provide independent evidence for Kivo’s reported patient outcomes or its estimated annual savings per member. It does not identify the methodology or baseline used for that savings figure. The timing and scope of expansion into other chronic conditions, along with any changes to payer coverage, remain unclear.
Kivo’s Two-Year Growth Target
Kivo says it plans to use the financing to expand nationwide and reach tens of thousands of patients within the next two years. The company has also said it intends to adapt its care model for other high-cost chronic illnesses. It has not announced a launch schedule, new condition areas or specific geographic milestones.
Further updates on market availability, patient enrollment and clinical or financial results will help show how the expansion is progressing. The funding report does not provide a date for those updates.
Key Questions
How much did Kivo Health raise?
Kivo raised $10 million in Series A financing, bringing its total financing to $16 million, according to Home Health Care News.
Who invested in the round?
Allumia Ventures led the round. Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures also participated.
What care does Kivo currently provide?
Kivo focuses on virtual home care for COPD. Its program includes a home kit and scheduled online support from respiratory therapists, including small-group sessions described as twice weekly for nine weeks.
What does Kivo plan to do with the funding?
The company says it will use the money for nationwide expansion and intends to extend its care model to other high-cost chronic illnesses. Specific launch markets and timelines have not been announced.
Has Kivo independently demonstrated its claimed cost savings?
The source report attributes an estimate of $8,245 in annual savings per member to Kivo. It does not include the study methods or independent verification, so the figure should be treated as a company claim.
Source: homehealthcarenews.com
